Biogen’s sales for its new Alzheimer’s drug fell short of Wall Street expectations, with the drugmaker reporting on Wednesday that it brought in millions less than anticipated from aduhelm in the third quarter.The first Alzheimer’s drug approved by…
Source: The Hill
Sales of new Alzheimer's drug fall short of expectations
Published in Make America Late Again
Be First to Comment